“Bimekizumab impact on patient-reported outcomes in patients with moderate to severe hidradenitis suppurativa: Pooled Week 48 results from BE HEARD I&II”, J of Skin, vol. 8, no. 6, p. s476, Nov. 2024, doi: 10.25251/skin.8.supp.476.